The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study
Authors:
- Tomas Thor AgustssonTATomas Thor Agustsson
- Tinna BaldvinsdottirTBTinna Baldvinsdottir
- Jon G JonassonJJJon G Jonasson
- Elinborg OlafsdottirEOElinborg Olafsdottir
- Valgerdur SteinthorsdottirVSValgerdur Steinthorsdottir
- Gunnar SigurdssonGSGunnar Sigurdsson
- Arni V ThorssonATArni V Thorsson
- Paul V CarrollPCPaul V Carroll
- Márta KorbonitsMKMárta Korbonits
- Rafn BenediktssonRBRafn Benediktsson
Top Cited Papers
- 1 November 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 173 (5) , 655-664
Abstract
Objective Pituitary adenomas (PA) are among the most common human neoplasms. To describe the epidemiology and assess the disease burden of clinically significant PAs, population-based studies are needed. Iceland has a small well-defined population. The aim of this study is to describe the epidemiology of PAs in Iceland over an expanded period of time. Design This is a retrospective observational study, including all PAs diagnosed in Iceland from 1955 to 2012. Methods Extensive clinical information was gathered in a database. Prevalence rates for all PA subtypes were calculated along with standardized incidence rates (SIR). Sex ratios and relationships with adenoma size, age, and symptoms were assessed. Results We identified 471 individuals: 190 men and 281 women. Total prevalence in 2012 was 115.57/100 000, prolactinomas were most prevalent (54.37/100 000) followed by non-functioning adenomas (NFPAs) (42.32/100 000). Throughout the period, NFPAs were most common (43.0%) followed by prolactinomas (39.9%) and 11.3% had acromegaly and 5.7% Cushing's disease. Women are diagnosed younger with smaller adenomas. Total SIR has increased significantly and is now 5.8/100 000 per year. Conclusion In this nationwide study spanning six decades, we have confirmed PAs rising prevalence and incidence rates noted in recent studies. We demonstrated higher overall prevalence and incidence rates than ever previously recorded with an increasing predominance of NFPAs, which is not explained by incidental findings alone. There is a relationship with the introduction of imaging modalities, but the vast majority of patients are symptomatic at diagnosis. This underlines the importance of increased awareness, education, and appropriate allocation of resources for this growing group of patients.Keywords
This publication has 21 references indexed in Scilit:
- Prevalence and incidence of pituitary adenomas: a population based study in MaltaPituitary, 2012
- Excess mortality for patients with residual disease following resection of pituitary adenomasPituitary, 2011
- Multigenerational Information: The Example of the Icelandic Genealogy Database2010
- Incidence of Pituitary Adenomas in Northern Finland in 1992–2007The Journal of Clinical Endocrinology & Metabolism, 2010
- Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK)Clinical Endocrinology, 2010
- Disease‐specific impairments in quality of life during long‐term follow‐up of patients with different pituitary adenomasClinical Endocrinology, 2008
- Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearanceEuropean Journal of Endocrinology, 2008
- High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, BelgiumThe Journal of Clinical Endocrinology & Metabolism, 2006
- Quality of Life Is Decreased after Treatment for Nonfunctioning Pituitary MacroadenomaThe Journal of Clinical Endocrinology & Metabolism, 2006
- Association between premature mortality and hypopituitarismThe Lancet, 2001